Author:
Pain J. B.,Lê M. P.,Caseris M.,Amiel C.,Lassel L.,Charpentier C.,Desnoyer A.,Farnoux C.,Pialoux G.,Descamps D.,Peytavin G.
Abstract
ABSTRACTWe describe the pharmacokinetics of dolutegravir (DTG) in a premature neonate after maternal intensification of an antiretroviral (ARV) regimen by adding DTG. During the last 2 weeks of pregnancy, the ARV was tenofovir-emtricitabine, atazanavir-ritonavir, and DTG (50 mg once daily). From the interaction between atazanavir and DTG via CYP3A4 and UGT1A1 and placental efflux transporter inhibition and considering the infant's probable enzymatic immaturity, the DTG elimination half-life was estimated to be 4-fold longer in neonates than in adults.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference9 articles.
1. Anonymous. 2014. Tivicay (dolutegravir), summary of product characteristics. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204790s002lbl.pdf. Last accessed, January 2015.
2. Anonymous. 2013. Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts rapport 2013 sous la direction du Philippe Morlat et sous l'égide du CNS et de l'ANRS. http://www.sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf. Last accessed, January 2015. (In French.)
3. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry;Biomed Chromatogr,2007
4. Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women;Pregnancy and Newborn Clinical Outcome Group in HIV Infection (PANCOH);Curr HIV Res,2009
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献